¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - Áö¿ª ºÐ¼®
Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Speciality, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2025-2035
»óǰÄÚµå : 1754871
¸®¼­Ä¡»ç : BIS Research Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,900 £Ü 6,718,000
PDF and Excel (1-3 User License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,500 £Ü 10,283,000
PDF and Excel (Global License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀº Èñ±ÍÁúȯÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í ÀÌ·¯ÇÑ Áúº´ÀÇ À¯º´·üÀÇ »ó½ÂÀ» ¹è°æÀ¸·Î Å« ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù.

ƯÈ÷ ¼Ò¾Æ ȯÀÚÃþÀÇ Á¶±â Áø´Ü°ú ¿¹¹æ¿¡ ´ëÇÑ °ü½É Áõ°¡°¡ ½ÃÀå È®´ë¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀº °è¼Ó ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖÀ¸¸ç, Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç´Â Çö´ëÀÇ Á¤¹ÐÀÇ·á¿¡¼­ Áß¿äÇÑ ¿ä¼Ò°¡µÇ°í ÀÖ½À´Ï´Ù.

Áúº´ À¯Çüº°·Î ³»ºÐºñ ¹× ´ë»ç Áúȯ ºÎ¹®ÀÌ °è¼Ó ¿ìÀ§

³»ºÐºñ Áúȯ ¹× ´ë»ç¼º ÁúȯÀº ÀÏ¹Ý Áý´Ü¿¡¼­ ¸Å¿ì ³ôÀº À¯º´·üÀ» ³ªÅ¸³»¸ç, ±× Áø´Ü°ú °ü¸®´Â ƯÈ÷ º¹ÀâÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀ» Áø´ÜÇÏ·Á¸é Á¾Á¾ Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)À» Æ÷ÇÔÇÑ Èñ±Í Áúȯ À¯ÀüÀÚ °Ë»ç¿Í Á¤È®ÇÑ ½Äº° ¹× È¿°úÀûÀÎ °ü¸®¸¦ º¸ÀåÇϱâ À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®, ½Å»ý¾Æ ¼±º° °Ë»ç, ºÐÀÚ Áø´Ü ±â¼úÀÌ ÇÊ¿äÇÕ´Ï´Ù.

Àü¹® ºÐ¾ßº°·Î´Â ºÐÀÚ À¯ÀüÀÚ °Ë»ç°¡ ÁÖ·Î ¿ìÀ§¸¦ À¯Áö

ºÐÀÚ À¯ÀüÀÚ °Ë»çÀÇ ÀαⰡ ³ô¾ÆÁö°í ÀÖ´Â ÁÖ¿ä ¿äÀÎÀº Èñ±ÍÁúȯ¿¡ ¿µÇâÀ» ¹ÞÀº °³ÀÎÀ̳ª °¡Á·¿¡°Ô À¯Àü »ó´ãÀ̳ª °¡Á· °èȹ¿¡ ÇÊ¿äÇÑ Áß¿äÇÑ Á¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡ ÀÖ½À´Ï´Ù. ¼ºÀ» °¡Á·ÀÌ ÀÌÇØÇϰí Â÷¼¼´ë¿¡ ´ëÇÑ À¯Àü À§ÇèÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ, ÀÌ °Ë»ç´Â ½Å»ý¾Æ¿¡¼­ À¯Àü¼º ÁúȯÀÇ ½Äº°¿¡µµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖÀ¸¸ç, Á¶±â °³ÀÔ°ú ½Ã±â ÀûÀýÇÑ Ä¡·á °³½Ã¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á, º¸´Ù ¾çÈ£ÇÑ °Ç°­ °á°ú·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

ÇüÁúº°·Î´Â À¯Àü¼º ÇüÁúÀÇ ºÎ¹®ÀÌ °¡Àå ³ôÀº ¼ºÀåÀ» ³ªÅ¸³»´Â Àü¸Á

À¯Àü¼º ÇüÁúÀº ºÎ¸ð¿¡¼­ ÀÚ½ÄÀ¸·Î DNA¸¦ ÅëÇØ Àü´ÞµÇ´Â À¯ÀüÀû Ư¡°ú Áúº´À» ÀǹÌÇÕ´Ï´Ù. Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç´Â ÀÌ·¯ÇÑ À¯Àü¼º µ¹¿¬º¯À̸¦ È®ÀÎÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Á¶±â Áø´Ü, À§Çè Æò°¡, ´ç»çÀÚ ¹× ±× °¡Á·¿¡ ´ëÇÑ ÀûÀýÇÑ ÀÇ·á ÆÇ´ÜÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

±â¼úº°·Î, Â÷¼¼´ë ½ÃÄö½Ì(NGS)Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀ» º¸¿©ÁÙ Àü¸Á

NGS ±â¼úÀº ´ÜÀÏ ¿°±â µ¹¿¬º¯ÀÌ(SNV), »ðÀÔ, °á½Ç, ±¸Á¶Àû À籸¼º µîÀÇ À¯ÀüÀû º¯À̸¦ °í°¨µµÀÌ°í °íÁ¤¹Ðµµ·Î °ËÃâÇÒ ¼ö ÀÖ´Â Á¡ÀÌ Å« Ư¡ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÀ¿ëµÇ¾î ƯÁ¤ Èñ±Í À¯Àü¼º Áúȯ°ú °ü·ÃµÈ žÆÀÇ ¿°»öü ÀÌ»ó °ËÃâÀ» Áö¿øÇÔÀ¸·Î½á Á¶±â °³ÀÔ°ú ÀÇÇÐÀû ÀÇ»ç °áÁ¤¿¡µµ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Áß±¹ÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç½ÃÀå È®´ë´Â Àα¸ ¸¹À½À¸·Î ÀÎÇÑ Èñ±ÍÁúȯÀÇ ³ôÀº À¯º´·ü, Á¤Ã¥È¯°æÀÇ ²ÙÁØÇÑ °³¼±, Áø´Ü ¹× Ä¡·á ºÐ¾ß¿¡¼­ÀÇ Çù·Â üÁ¦¸¦ °­È­ÇÏ´Â Á¤ºÎ ÁÖµµÀÇ ´ëó³ª ÆÄÆ®³Ê½Ê¿¡ ÀÇÇØ ÃßÁøµÇ°í ¶ÇÇÑ Àεµ¿Í È£ÁÖ¿Í °°Àº ±¹°¡µµ ¿¹Ãø ±â°£ µ¿¾È Å« ½ÃÀå ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Èñ±ÍÁúȯ¿¡ ´ëÇÑ ÀÎÁö Çâ»ó, ÀÇ·á ÀÎÇÁ¶ó Á¤ºñ, À¯ÀüÀÚ °Ë»ç ±â¼úÀÇ Áøº¸°¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ÁÖ¿ä µ¿Çâ, ½ÃÀå ¿µÇâ¿äÀÎ ºÐ¼®, ¹ý±ÔÁ¦ ȯ°æ, ÀÓ»ó½ÃÇè µ¿Çâ, ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø, °¢Á¾ ±¸ºÐ¡¤Áö¿ª, ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®Çß½À´Ï´Ù.

¸ñÂ÷

ÁÖ¿ä ¿ä¾à

Á¦1Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : °³¿ä

Á¦2Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Áúȯ À¯Çüº°

Á¦3Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Á¦°ø ±¸ºÐº°

Á¦4Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Àü¹® ºÐ¾ßº°

Á¦5Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : »ùÇà À¯Çüº°

Á¦6Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ÇüÁú À¯Çüº°

Á¦7Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ±â¼úº°

Á¦8Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ¿¬·ÉÃþº°

Á¦9Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå :Áö¿ªº°

Á¦11Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : °æÀï º¥Ä¡¸¶Å·°ú ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦12Àå Á¶»ç ¹æ¹ý

SHW
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Introduction of Rare Disease Genetic Testing

Before the advent of next-generation sequencing (NGS), including whole-genome sequencing (WGS) and whole-exome sequencing (WES), physicians primarily relied on Sanger sequencing for rare disease genetic testing. However, this method was highly time-consuming, often leading to delays in diagnosis. Until definitive results were available, physicians had to rely on a general diagnostic approach, which prolonged the treatment process for rare disease patients.

According to BIS Research, the global rare disease genetic testing market includes various panels and tests designed to detect genetic abnormalities associated with rare diseases. These tests primarily consist of polymerase chain reaction (PCR)-based and NGS-based techniques, along with specialized panels and assays. Some of the most used rare disease genetic testing panels focus on conditions related to gastroenterology, endocrinology and metabolism, and neurology.

Cutting-edge technologies such as WGS and WES have revolutionized rare disease genetic testing by providing comprehensive genetic analysis. WGS examines an individual's entire genome, while WES focuses on protein-coding regions, helping identify genetic variations, mutations, or abnormalities responsible for rare diseases. These advanced rare disease genetic testing methods have significantly improved diagnostic accuracy and efficiency, enabling earlier and more precise disease identification, and ultimately enhancing patient outcomes.

Industrial Impact on Rare Disease Genetic Testing Market

The global rare disease genetic testing market has witnessed significant growth, driven by the increasing demand for early detection of rare diseases and the rising prevalence of these conditions. The growing emphasis on early diagnosis and prevention, particularly in paediatric populations worldwide, further contributes to market expansion. Rare disease genetic testing holds immense potential to revolutionize healthcare by enabling advanced diagnostic solutions, improving patient outcomes, and accelerating research efforts. Additionally, factors such as increased patient demand and the reduced turnaround time of rare disease genetic testing continue to drive market growth, making it a crucial component of modern precision medicine.

Market Segmentation of Rare Disease Genetic Testing Market:

Segmentation 1: by Disease Type

Endocrine and Metabolism Disease Segment to Continue its Dominance as the Leading Disease Type

Endocrine and metabolic diseases are highly prevalent in the general population, making their diagnosis and management particularly complex. Diagnosing these conditions often involves rare disease genetic testing, including next-generation sequencing (NGS), along with biomarker analysis, newborn screening, and molecular diagnostic techniques to ensure accurate identification and effective management.

Segmentation 2: Offering

Services to Witness the Highest Growth Between 2025 and 2035

Services are uniquely designed to cater to the specific needs of individuals affected by rare diseases, healthcare professionals, and researchers in this field. These services enhance the use of diagnostic products and support comprehensive, personalized rare disease genetic testing, ensuring accurate diagnosis and effective disease management.

Segmentation 3: by Specialty Type

Molecular Genetic Test to Continue its Dominance as the Leading Specialty Type

The growing popularity of molecular genetic testing is primarily driven by its ability to provide essential information for genetic counseling and family planning for individuals and families affected by rare diseases. By detecting specific genetic mutations, rare disease genetic testing helps families understand the likelihood of disease inheritance and evaluate the risk of passing the condition to future generations. Additionally, this testing plays a crucial role in identifying genetic disorders in newborns, enabling early intervention and timely treatment initiation for better health outcomes.

Segmentation 4: by Sample Type

Blood Sample to Witness the Highest Growth Between 2025 and 2035

Blood samples are processed to isolate various components, including white blood cells, serum, or plasma, which are then analyzed to detect genetic abnormalities, identify biochemical markers, or explore other diagnostic indicators. Rare disease genetic testing utilizes advanced methods such as PCR, DNA sequencing, and microarrays on these blood samples to pinpoint specific genetic mutations associated with rare diseases. These techniques enhance diagnostic accuracy, enabling early detection and informed medical decision-making.

Segmentation 5: by Trait Type

Inherited Trait to Witness the Highest Growth between 2025 and 2035

Inherited traits are genetic characteristics or conditions transmitted from parents to their offspring through DNA. These traits arise from variations or mutations in specific genes, which can elevate the risk of developing certain rare diseases. Rare disease genetic testing plays a crucial role in identifying these inherited mutations, enabling early diagnosis, risk assessment, and informed medical decisions for affected individuals and their families.

Segmentation 6: by Technology

Next-Generation Sequencing (NGS) to Witness the Highest Growth between 2025 and 2035

Next-generation sequencing (NGS) technology offers enhanced sensitivity and specificity in detecting genetic variants, including single-nucleotide variants (SNVs), insertions, deletions, and structural rearrangements. It plays a crucial role in rare disease genetic testing, enabling comprehensive genomic analysis for accurate diagnosis. Additionally, NGS extends its applications to non-invasive prenatal testing, facilitating the detection of fetal chromosomal abnormalities associated with certain rare genetic conditions, thereby supporting early intervention and informed decision-making.

Segmentation 7: by Age Group

Prenatal to Witness the Highest Growth between 2025 and 2035

Prenatal testing and diagnostics are essential for identifying potential rare diseases and congenital abnormalities in the foetus. As part of rare disease genetic testing, methods such as chorionic villus sampling (CVS) and amniocentesis are utilized to detect genetic disorders or developmental issues early in pregnancy. These advanced diagnostic techniques enable timely medical intervention, informed decision-making, and improved prenatal care for at-risk pregnancies.

Segmentation 8: by End User

Hospitals to Witness the Highest Growth Between 2025 and 2035

Hospitals are at the forefront of integrating syndromic testing panels into routine healthcare practices, significantly enhancing diagnostic capabilities in rare disease genetic testing. Leading healthcare institutions, particularly in North America and Europe, and increasingly in the Asia-Pacific region, have adopted these advanced testing panels and assays to deliver more precise and timely diagnoses. This integration supports improved patient care by enabling comprehensive genetic analysis, facilitating early detection, and guiding targeted treatment strategies.

Segmentation 9: by Region

The expansion of the rare disease genetic testing market in China is driven by the high prevalence of rare diseases due to its large population, a progressively favorable policy landscape, and government-led initiatives and partnerships aimed at enhancing collaboration in rare disease diagnosis and treatment. Additionally, countries like India and Australia are expected to experience significant market growth during the forecast period from 2025 to 2035, fuelled by increasing awareness, improved healthcare infrastructure, and advancements in rare disease genetic testing technologies.

Recent Developments in the Rare Disease Genetic Testing Market

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

Market Challenges:

Significant Capital Requirement for Research and Development Hindering Global Expansion Efforts: The substantial capital required for research and development (R&D) presents a significant challenge for the global rare disease genetic testing market. Advancements in rare disease genetic testing demand extensive genetic studies, clinical trials, and the development of innovative diagnostic tools and therapies, all of which require considerable financial investment. These efforts involve specialized expertise, advanced laboratory infrastructure, regulatory compliance, and patient recruitment, further escalating costs. The high expenses associated with R&D act as a barrier, particularly for smaller companies and research institutions with limited resources, restricting their ability to pursue comprehensive research in rare disease genetic testing. Additionally, since rare diseases impact a small patient population, the limited commercial market potential for diagnostics and treatments makes it challenging to attract sufficient private investment, further hindering progress in rare disease genetic testing.

Market Opportunities:

How Can Rare Disease Genetic Testing Market Report Add Value to an Organization?

Product/Innovation Strategy: The global rare disease genetic testing market is comprehensively segmented across multiple categories, including disease type, specialty type, sample type, end-user, and region. This segmentation provides valuable insights into the market landscape, helping readers identify which segments hold the largest market share and which are poised for significant growth in the coming years. Understanding these divisions enables stakeholders to assess trends, target key opportunities, and strategize effectively for advancements in rare disease genetic testing.

Growth/Marketing Strategy: Between January 2021 and June 2023, partnerships, collaborations, product launches, and upgrades dominated key developments in the global rare disease genetic testing market, accounting for approximately 86.2% of total advancements. These strategic initiatives have played a crucial role in driving innovation, expanding diagnostic capabilities, and enhancing accessibility to rare disease genetic testing, positioning the market for continued growth and technological progress.

Competitive Strategy: The global rare disease genetic testing market comprises numerous established players actively expanding their offerings of tests, panels, and assays. Key industry participants analyzed in the study include leading companies that provide specialized disease-specific panels and multiplex instruments, driving advancements in rare disease genetic testing. These players play a crucial role in enhancing diagnostic accuracy, expanding test accessibility, and fostering innovation to support the growing demand for genetic testing solutions.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

Primary Research:

The primary sources involve industry experts in genomic sequencing, including the market players offering rare disease genetic testing kits/assays and panels and instruments. Resources such as physicians, global sales heads, regional marketing managers, distributors, CXOs, and investors have been interviewed to obtain and verify both qualitative and quantitative aspects of rare disease genetic testing research study.

The key data points taken from the primary sources include:

Secondary Research

Open Sources

The key data points taken from the secondary sources include:

Table of Contents

Executive Summary

Scope of Study

Research Methodology

1. Global Rare Disease Genetic Testing Market Overview

2. Global Rare Disease Genetic Testing Market (By Disease Type), $Million, 2023-2035

3. Global Rare Disease Genetic Testing Market (By Offering), $Million, 2023-2035

4. Global Rare Disease Genetic Testing Market (By Specialty Type), $Million, 2023-2035

5. Global Rare Disease Genetic Testing Market (By Sample Type), $Million, 2023-2035

6. Global Rare Disease Genetic Testing Market (By Trait Type), $Million, 2023-2035

7. Global Rare Disease Genetic Testing Market (By Technology), $Million, 2023-2035

8. Global Rare Disease Genetic Testing Market (By Age Group), $Million, 2023-2035

9. Global Rare Disease Genetic Testing Market (By End User), $Million, 2023-2035

10. Global Rare Disease Genetic Testing Market (By Region), $Million, 2023-2035

11. Global Rare Disease Genetic Testing Market - Competitive Benchmarking and Company Profiles

12. Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â